Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Ischaemia-reperfusion
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatIschaemia-reperfusionOther / unspecifiedSprague-DawleyMaleOral30, 100 and 300 mg/kgAcute pretreatment before ischaemia-reperfusion and subacute treatment for 3 da…
Model: Gastric ischaemia and reperfusion induced gastric lesion
Pretreatment at 100 mg/kg reduced myeloperoxidase activity by 38 percent without a clear macroscopic effect on lesion area. Three days of treatment at 30 and 100 mg/kg reduced lesion area by 95 percent and 89 percent respectively (p<0.05), with myeloperoxidase reduced by 70 to 78 percent and matrix…
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.